Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HLX37, a dual-specific antibody injection for treating advanced/metastatic solid tumors [1] Group 1: Company Developments - The approved product, HLX37, is a recombinant humanized dual-specific antibody targeting PD-L1 and VEGF, developed independently by the group [1] - The company plans to conduct Phase I clinical trials for HLX37 in China once conditions are met [1] Group 2: Product Details - Preclinical studies indicate that HLX37 can inhibit tumor growth and demonstrates good safety profiles [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HLX37, a dual-specific antibody injection for treating advanced/metastatic solid tumors [1] Group 1: Company Developments - The approved product, HLX37, is a recombinant humanized anti-PD-L1 and anti-VEGF dual-specific antibody injection [1] - The company plans to conduct Phase I clinical trials for HLX37 in China once conditions are met [1] - Preclinical studies indicate that HLX37 can inhibit tumor growth and has good safety profiles [1]

上海复星医药（集团）股份有限公司 关于控股子公司药品获临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 证券代码：600196 股票简称：复星医药 编号：临 2025-185 1 三、风险提示 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"） 控股子公 司上海复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"） 收到国家药品监督管理局关于同意 HLX37 注射液（即重组人源化抗 PD-L1 与抗 VEGF 双特异性抗体注射液；以下简称"HLX37"）用于治疗晚期/转移性实体瘤患者开展 临床试验的批准。复宏汉霖拟于条件具备后于中国境内 1开展 HLX37 的Ⅰ期临床试验。 二、HLX37 的基本信息 HLX37 是本集团（本公司及控股子公司/单位，下同）自主研发的重组人源化抗 PD-L1 与抗 VEGF 双特异性抗体，拟用于治疗晚期/转移性实体瘤。截至目前的临床 前研究表明，HLX37 能够抑制肿瘤生长，且具有良好的安全性。 截至 2025 年 10 月，本集团（即本公司及控 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HLX37 injection for treating advanced/metastatic solid tumor patients [1] Group 1: Clinical Trial Approval - The approval allows for the initiation of Phase I clinical trials for HLX37 in mainland China once conditions are met [1] - The clinical trial is aimed at patients with advanced or metastatic solid tumors [1] Group 2: Research and Development Investment - As of October 2025, the cumulative R&D investment for HLX37 by the group is approximately RMB 50.23 million (unaudited) [1]

Summary of FOSUN International Conference Call Company Overview - **Company**: FOSUN International - **Industry**: Diversified Investments, Pharmaceuticals, Insurance, Consumer Goods Key Points Strategic Transformation - FOSUN International is undergoing a strategic transformation focusing on core businesses and exiting non-core assets, aiming to increase overseas revenue contribution to 60% and significantly reduce debt levels, targeting interest-bearing liabilities below 60 billion RMB and public market debt to 25% [2][6][3] Business Segments - **Domestic Business**: - Focus on consumer sectors, including gold jewelry and cultural tourism through Yuyuan [4] - Innovation in pharmaceuticals represented by FOSUN Pharma [4][5] - **Overseas Business**: - Key investments in Portuguese insurance and consumer brands like Club Med, contributing to nearly 30% of total overseas revenue [4][10] Financial Goals - Plans to reduce interest-bearing debt from a peak of 120 billion RMB to 89 billion RMB, with a further target of 60 billion RMB [6] - Aiming to restore group operating profit and net profit attributable to shareholders to 10 billion RMB, while gradually increasing the dividend payout ratio from 20% to 50% over the next 3-5 years [6][13] Innovation in Pharmaceuticals - FOSUN Pharma is accelerating its transition to innovative drugs, with expectations for rapid growth post-2027, supported by a global R&D center and innovative drug platform [2][9] - Currently, there are multiple innovative drugs in the pipeline with global sales potential between 5 billion to 10 billion USD [9] Geographic Risk Management - The company employs a strategy combining globalization with local operations to mitigate geopolitical risks, particularly in Europe and North America [7][11] - In Europe, the Portuguese insurance business is expected to maintain a premium income growth rate of 10%-15% over the next five years, with significant profit growth potential due to low current ROE [10] Asset Disposal Strategy - FOSUN International has identified approximately 90 billion to 100 billion RMB worth of assets for disposal, including real estate and non-core investments, aiming to generate cash flow to reduce debt [12] - Specific assets include real estate valued at around 30 billion RMB and non-core secondary market holdings [12] Dividend Policy - The company plans to gradually increase its dividend payout ratio to enhance shareholder returns, with a target of achieving 10 billion RMB in operating profit [13] Competitive Position in Pharmaceuticals - FOSUN Pharma is transitioning from generics to innovative drugs, with significant investments in R&D and a focus on global commercialization capabilities [14][15] - The company is committed to maintaining a competitive edge through substantial annual investments in innovation and development [15] Real Estate Disposal Insights - The company evaluates real estate project sales based on market conditions and potential for appreciation, indicating a flexible pricing strategy [16]

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the first nine months of 2025 [1]. Industry Summary - In September 2025, the production of chemical pharmaceutical raw materials in China was 295,000 tons, representing a year-on-year decrease of 3.6% [1]. - Cumulatively, from January to September 2025, the total production of chemical pharmaceutical raw materials reached 2.721 million tons, showing a cumulative growth of 1.2% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the chemical pharmaceutical sector include Heng Rui Medicine (600276), East China Pharmaceutical (000963), Lizhu Group (000513), Baiyunshan (600332), North China Pharmaceutical (600812), Haizheng Pharmaceutical (600267), Fosun Pharmaceutical (600196), Kelun Pharmaceutical (002422), Enhua Pharmaceutical (002262), and Xianju Pharmaceutical (002332) [1].

Core Viewpoint - Fosun International (00656.HK) announced a mutual supply framework agreement between its subsidiary Fosun Pharma and Chongqing Pharmaceutical Holdings, effective from January 1, 2026, to December 31, 2028, for a duration of three years [1] Group 1 - The agreement involves Fosun Pharma supplying and selling products to Chongqing Pharmaceutical Holdings while also purchasing products from them [1] - Both companies will provide mutual services as part of the agreement [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 持續關連交易 (1)訂立重藥控股互供框架協議 (2)訂立租賃框架協議 及 (3)訂立復星國際互供框架協議 重藥控股互供框架協議 董事會宣佈，本公司與重藥控股於2025年11月28日訂立重藥控股互供框架協議，內容有 關本集團向重藥控股集團供應銷售產品及購買採購產品，以及本集團與重藥控股集團互 相提供服務，自2026年1月1日起至2028年12月31日止，為期3年。 租賃框架協議 承租框架協議 董事會宣佈，復星國際與本公司於2025年11月28日訂立承租框架協議，內容有關本集團 相 關 成 員（ 作 為 承 租 人 ）承 租 相 關 復 星 國 際 物 業 ， 自 2026 年 1 ...

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 召開2025 年第二次臨時股東會的提示性公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司借款續展暨關聯交易的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 1 月2 8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 （股份代號：02196） 海外 ...